BioMarin Pharmaceutical/ US09061G1013 /
| 8/12/2022 9:59:59 PM | Chg. -0.07 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 95.04USD | -0.07% | 59,996 Turnover: 5.69 mill. |
-Bid Size: - | -Ask Size: - | 17.63 bill.USD | 0.00% | - |
Assets
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 896.7000 | 948.7000 | 1,010.9000 | 1,032.5000 | 1,035.5000 | ||||||
| Intangible Assets | 517.5000 | 491.8000 | 456.6000 | 417.3000 | 388.7000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | - | - | - | - | - | ||||||
| Inventories | 475.8000 | 530.9000 | 680.3000 | 698.5000 | 776.7000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 598 | 494 | 437.4000 | 649.2000 | 587.3000 | ||||||
| Current Assets | 2,207.1000 | 2,056.2000 | 1,942.1000 | 2,342.2000 | 2,274.4000 | ||||||
| Total Assets | 4,633.1000 | 4,427.1000 | 4,690 | 5,848 | 6,003.3000 | ||||||
Liabilities
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Long-term debt | - | - | - | - | - | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,824.5000 | 1,459.2000 | 1,567.7000 | 1,742 | 1,732.6000 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | 2,808.7000 | 2,967.9000 | 3,122.4000 | 4,106 | 4,270.7000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 4,633.1000 | 4,427.1000 | 4,690 | 5,848 | 6,003.3000 | ||||||
Income Statement
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,313.6000 | 1,491.2000 | 1,704 | 1,860.5000 | 1,846.3000 | ||||||
| Depreciation (total) | 46.5000 | 48.8000 | 74.1000 | 66.7000 | 69.9000 | ||||||
| Operating Result | -14.7000 | -123.5000 | -100.5000 | -36.8000 | -82.3000 | ||||||
| Interest Income | -27.8000 | -20.9000 | -.8000 | -12.7000 | -4.8000 | ||||||
| Income Before Taxes | -35.9000 | -142.7000 | -94.8000 | -42.3000 | -75.4000 | ||||||
| Income Taxes | 81.2000 | -65.5000 | -71 | -901.4000 | -11.3000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -117 | -77.2000 | -23.8000 | 859.1000 | -64.1000 | ||||||
Per Share
Cash Flow
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -8.8000 | 20.2000 | 48.3000 | 85.4000 | 304.5000 | ||||||
| Cash Flow from Investing Activities | -305.5000 | 264.4000 | -31 | -53.6000 | -366.3000 | ||||||
| Cash Flow from Financing | 507.1000 | -388 | -74.7000 | 181.1000 | -.0500 | ||||||
| Decrease / Increase in Cash | 189.7000 | -104 | -56.5000 | 211.7000 | -61.9000 | ||||||
| Employees | 2,581 | 2,849 | 3,001 | 3,059 | 3,045 | ||||||